-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $176

Benzinga·02/17/2026 19:36:11
Listen to the news
JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $177 to $176.